Table 5.
Multivariate linear regression analyses between Influencers and CD4+ cell count increase, stratified analyses by BMI.
| Variable | BMI < 18.5 | BMI 18.5–25.0 | BMI ≥ 25.0 |
|---|---|---|---|
| Gender | −2.2 (−83.5, 79.0) | −6.0 (−56.3, 44.2) | −38.9 (−211.5, 133.6) |
| Age at follow-up | 0.4 (−1.2, 2.0) | −0.4 (−1.4, 0.6) | −1.5 (−4.6, 1.6) |
| Duration from HIV diagnosis to HAART start (months)b | −24.6 (−58.5, 9.2) | −13.5 (−31.1, 4.1) | −50.7 (−138.3, 36.9) |
| Duration of HAART (months)b | −5.0 (−43.3, 33.3) | −1.6 (−18.7, 15.5) | 18.5 (−41.1, 78.0) |
| Transmission route | 1.6 (−29.5, 32.6) | 13.1 (−8.7, 34.9) | −32.4 (−133.7, 68.8) |
| WHO clinical stage | 20.0 (−8.3, 48.4) | 1.3 (−15.0, 17.6) | 52.8 (−8.9, 114.6) |
| Co-trimoxazolea | −93.7 (−157.8, 29.5)∗ | −82.0 (−114.9, −49.1)∗ | −595.7 (−756.2, −435.2)∗ |
| HAART optionsa | 18.1 (−12.5, 48.6) | 6.9 (−9.7, 23.5) | 28.7 (−72.1, 129.4) |
| HAART replacement | −54.2 (−101.2, −7.2)∗ | −5.2 (−36.0, 25.6) | −65.2 (−202.0, 71.6) |
| Crb | 1.5 (0.1, 3.0)∗ | 0.7 (−0.2, 1.6) | −1.5 (−4.3, 1.3) |
aInfluencers in baseline, bInfluencers in follow-up, ∗P < 0.05. The multivariate linear regression model included gender, age at follow-up, duration from HIV diagnosis to HAART start, duration of HAART, transmission route, WHO clinical stage, co-trimoxazole, HAART options, HAART replacement, cr.